BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-7868 [PMID: 26167086 DOI: 10.3748/wjg.v21.i25.7860]
URL: https://www.wjgnet.com/1948-5182/full/v21/i25/7860.htm
Number Citing Articles
1
Katherine T. Brunner, Cameron J. Henneberg, Robert M. Wilechansky, Michelle T. Long. Nonalcoholic Fatty Liver Disease and Obesity TreatmentCurrent Obesity Reports 2019; 8(3): 220 doi: 10.1007/s13679-019-00345-1
2
Michele Finotti, Maurizio Romano, Pasquale Auricchio, Michele Scopelliti, Marco Brizzolari, Ugo Grossi, Marco Piccino, Stefano Benvenuti, Giovanni Morana, Umberto Cillo, Giacomo Zanus. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical AlternativesJournal of Personalized Medicine 2021; 11(6): 499 doi: 10.3390/jpm11060499
3
Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D. Goodman, Keith Lindor. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitisHepatology 2018; 68(1): 361 doi: 10.1002/hep.29724
4
Henrik H. Hansen, Michael Feigh, Sanne S. Veidal, Kristoffer T. Rigbolt, Niels Vrang, Keld Fosgerau. Mouse models of nonalcoholic steatohepatitis in preclinical drug developmentDrug Discovery Today 2017; 22(11): 1707 doi: 10.1016/j.drudis.2017.06.007
5
Feliciano Chanana Paquissi. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic TargetsFrontiers in Immunology 2016; 7 doi: 10.3389/fimmu.2016.00490
6
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020Journal of Gastroenterology 2021;  doi: 10.1007/s00535-021-01796-x
7
Ramy Younes, Elisabetta Bugianesi. The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and MortalityCurrent Hepatology Reports 2018; 17(4): 336 doi: 10.1007/s11901-018-0422-x
8
Pavel Kraml. Lipid-lowering therapy in selected specific groups of patientsMedicína pro praxi 2020; 17(3): 151 doi: 10.36290/med.2020.029
9
Vasiliki Venetsanaki, Stergios A. Polyzos. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic PerspectivesCurrent Vascular Pharmacology 2019; 17(6): 546 doi: 10.2174/1570161116666180711121949
10
Jaime Bosch, Jordi Gracia-Sancho, Juan G Abraldes. Cirrhosis as new indication for statinsGut 2020; 69(5): 953 doi: 10.1136/gutjnl-2019-318237
11
Fabio Nascimbeni, Elisa Pellegrini, Simonetta Lugari, Alberto Mondelli, Serena Bursi, Giovanna Onfiani, Francesca Carubbi, Amedeo Lonardo. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foesAtherosclerosis 2019; 284: 66 doi: 10.1016/j.atherosclerosis.2019.02.028
12
Manal F. Abdelmalek. The clinical and economic burden of NAFLD: time to turn the tideNature Reviews Gastroenterology & Hepatology 2016; 13(12): 685 doi: 10.1038/nrgastro.2016.178
13
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou, Vasilios G. Athyros. The potential role of statins in treating liver diseaseExpert Review of Gastroenterology & Hepatology 2018; 12(4): 331 doi: 10.1080/17474124.2018.1439379
14
Stergios A. Polyzos, Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee, Christos S. Mantzoros. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitisMetabolism 2020; 111: 154203 doi: 10.1016/j.metabol.2020.154203
15
Somaya Albhaisi, Arun Sanyal. Recent advances in understanding and managing non-alcoholic fatty liver diseaseF1000Research 2018; 7: 720 doi: 10.12688/f1000research.14421.1
16
Yaron Rotman, Arun J Sanyal. Current and upcoming pharmacotherapy for non-alcoholic fatty liver diseaseGut 2017; 66(1): 180 doi: 10.1136/gutjnl-2016-312431
17
Hersh Shroff, Lisa B. VanWagner. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and ManagementCurrent Hepatology Reports 2020; 19(3): 315 doi: 10.1007/s11901-020-00530-0
18
Janet Lo, Michael T. Lu, Elli A. Kim, Eric Nou, Travis R. Hallett, Jakob Park, Udo Hoffmann, Steven K. Grinspoon. Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency VirusOpen Forum Infectious Diseases 2016; 3(2) doi: 10.1093/ofid/ofw062
19
Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Eric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, Mohammad Hassan Murad, Mazen Noureddin. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology 2019; 17(4): 616 doi: 10.1016/j.cgh.2018.06.011
20
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020Hepatology Research 2021;  doi: 10.1111/hepr.13688
21
Emir Muzurović, Dimitri P. Mikhailidis, Christos Mantzoros. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular riskMetabolism 2021; 119: 154770 doi: 10.1016/j.metabol.2021.154770
22
Sonali Paul, Michael Charlton. Surgical Issues in NASH: Bariatric Surgery and Liver TransplantationCurrent Hepatology Reports 2018; 17(4): 367 doi: 10.1007/s11901-018-0429-3
23
Maryam Mahjoubin-Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen L. Atkin, Christos S. Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosisMolecular Metabolism 2021; 50: 101049 doi: 10.1016/j.molmet.2020.101049
24
Farah Ahsan, Federico Oliveri, Harshit K Goud, Zainab Mehkari, Lubna Mohammed, Moiz Javed, Aldanah Althwanay, Ian H Rutkofsky. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic SteatohepatitisCureus 2020;  doi: 10.7759/cureus.10446
25
Niki Katsiki, Vasilios G Athyros. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatmentCurrent Medical Research and Opinion 2019; 35(7): 1305 doi: 10.1080/03007995.2019.1589152
26
Niki Katsiki, Dimitri P Mikhailidis. Lipids: a personal view of the past decadeHormones 2018; 17(4): 461 doi: 10.1007/s42000-018-0058-9
27
Frank Tacke. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosisExpert Opinion on Investigational Drugs 2018; 27(3): 301 doi: 10.1080/13543784.2018.1442436
28
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the BlockCurrent Vascular Pharmacology 2020; 18(2): 172 doi: 10.2174/1570161117666190405164313
29
Panagiotis Anagnostis, Konstantina Vaitsi, Panagiota Kleitsioti, Chrysanthi Mantsiou, Konstantinos Pavlogiannis, Vasilios G. Athyros, Dimitri P. Mikhailidis, Dimitrios G. Goulis. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trialsEndocrine 2020; 69(2): 249 doi: 10.1007/s12020-020-02302-8
30
Vasilios G. Athyros, Dimitri P. Mikhailidis. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practiceJournal of Diabetes and its Complications 2016; 30(1): 9 doi: 10.1016/j.jdiacomp.2015.07.012
31
Christian L. Horn, Amilcar L. Morales., Christopher Savard, Geoffrey C Farrell, George N. Ioannou. Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH Hepatology Communications 2021;  doi: 10.1002/hep4.1801
32
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?American Journal of Physiology-Gastrointestinal and Liver Physiology 2017; 312(6): G681 doi: 10.1152/ajpgi.00101.2017
33
Abdul M. Oseini, Arun J. Sanyal. Therapies in non-alcoholic steatohepatitis (NASH)Liver International 2017; 37: 97 doi: 10.1111/liv.13302
34
George N. Ioannou, Charles S. Landis, Ga‐Young Jin, W. Geoffrey Haigh, Geoffrey C. Farrell, Rahul Kuver, Sum P. Lee, Christopher Savard. Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic SteatohepatitisHepatology Communications 2019; 3(6): 776 doi: 10.1002/hep4.1348
35
Vasilios Gabriel Athyros. Multifactorial treatment of diabetic patients with cardiovascular disease to maximize resultsJournal of Diabetes and its Complications 2021; 35(6): 107904 doi: 10.1016/j.jdiacomp.2021.107904
36
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An updateMetabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
37
Maria-Styliani Kalogirou, Dimitrios Patoulias, Anna-Bettina Haidich, Evangelos Akriviadis, Emmanouil Sinakos. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trialsClinics and Research in Hepatology and Gastroenterology 2021; 45(3): 101568 doi: 10.1016/j.clinre.2020.10.012
38
Gregor Lorbek, Žiga Urlep, Damjana Rozman. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver diseasePharmacogenomics 2016; 17(11): 1273 doi: 10.2217/pgs-2016-0047
39
Francesca Cortese, Michele Gesualdo, Annamaria Cortese, Santa Carbonara, Fiorella Devito, Annapaola Zito, Gabriella Ricci, Pietro Scicchitano, Marco Matteo Ciccone. Rosuvastatin: Beyond the cholesterol-lowering effectPharmacological Research 2016; 107: 1 doi: 10.1016/j.phrs.2016.02.012
40
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis, Christos Mantzoros. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementMetabolism 2017; 71: 17 doi: 10.1016/j.metabol.2017.02.014
41
Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran. Non-alcoholic Fatty Liver Disease: A Clinical UpdateJournal of Clinical and Translational Hepatology 2017; (XX): XX doi: 10.14218/JCTH.2017.00013
42
Roberta de Pádua Borges, Nathália Abi Habib Degobi, Marcello Casaccia Bertoluci. Choosing statins: a review to guide clinical practiceArchives of Endocrinology and Metabolism 2020;  doi: 10.20945/2359-3997000000306
43
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis. Off target effects of statins shape total mortality?Journal of Drug Assessment 2016; 5(1): 4 doi: 10.3109/21556660.2016.1168302
44
Pakkapon Rattanachaisit, Paweena Susantitaphong, Kessarin Thanapirom, Roongruedee Chaiteerakij, Piyawat Komolmit, Pisit Tangkijvanich, Sombat Treeprasertsuk. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysisAsian Biomedicine 2018; 12(1): 3 doi: 10.1515/abm-2018-0026
45
Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis. Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary InterventionThe American Journal of Cardiology 2016; 117(2): 311 doi: 10.1016/j.amjcard.2015.11.001
46
Nikos Lazaridis, Emmanuel Tsochatzis. Current and future treatment options in non-alcoholic steatohepatitis (NASH)Expert Review of Gastroenterology & Hepatology 2017; 11(4): 357 doi: 10.1080/17474124.2017.1293523
47
Stefano Ciardullo, Gianluca Perseghin. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetesMetabolism 2021; 121: 154752 doi: 10.1016/j.metabol.2021.154752
48
Samarth Siddharth Patel, Mohammad Shadab Siddiqui. Current and Emerging Therapies for Non-alcoholic Fatty Liver DiseaseDrugs 2019; 79(1): 75 doi: 10.1007/s40265-018-1040-1
49
Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, Dimitri P. Mikhailidis. Dyslipidaemia in the elderly: to treat or not to treat?Expert Review of Clinical Pharmacology 2018; 11(3): 259 doi: 10.1080/17512433.2018.1425138
50
Won Dong Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim. Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemiaEuropean Journal of Gastroenterology & Hepatology 2020; 32(12): 1538 doi: 10.1097/MEG.0000000000001665
51
Eric P. Stahl, Devinder S. Dhindsa, Suegene K. Lee, Pratik B. Sandesara, Naga P. Chalasani, Laurence S. Sperling. Nonalcoholic Fatty Liver Disease and the HeartJournal of the American College of Cardiology 2019; 73(8): 948 doi: 10.1016/j.jacc.2018.11.050
52
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. NAFLD and StatinsDigestive Diseases and Sciences 2020; 65(10): 3052 doi: 10.1007/s10620-020-06505-x
53
D. van der Graaff, W.J. Kwanten, S.M. Francque. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitisMedical Hypotheses 2019; 122: 188 doi: 10.1016/j.mehy.2018.11.014
54
Mark D. Muthiah, Arun J. Sanyal. Current management of non‐alcoholic steatohepatitisLiver International 2020; 40(S1): 89 doi: 10.1111/liv.14355
55
Mazen Noureddin, Alice Zhang, Rohit Loomba. Promising therapies for treatment of nonalcoholic steatohepatitisExpert Opinion on Emerging Drugs 2016; 21(3): 343 doi: 10.1080/14728214.2016.1220533
56
Theodora Griva, Chrysoula Boutari, Konstantinos Tziomalos, Michael Doumas, Asterios Karagiannis, Vasilios G. Athyros. Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?The Open Hypertension Journal 2017; 9(1): 1 doi: 10.2174/1876526201709010001
57
Joost Boeckmans, Alessandra Natale, Karolien Buyl, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim M. Rodrigues. Human-based systems: Mechanistic NASH modelling just around the corner?Pharmacological Research 2018; 134: 257 doi: 10.1016/j.phrs.2018.06.029
58
Vasilios G Athyros. Statins for the Treatment of Non Alcoholic Fatty Liver Disease in Patients with Metabolic SyndromeJournal of Diabetes, Metabolic Disorders & Control 2016; 3(1) doi: 10.15406/jdmdc.2016.03.00057
59
Practical Diabetes Care2018; : 387 doi: 10.1002/9781119052210.ch13
60
V. G. Athyros, N. Katsiki, D. P. Mikhailidis. Letter: statins and cirrhosisAlimentary Pharmacology & Therapeutics 2017; 46(11-12): 1123 doi: 10.1111/apt.14355
61
Bubu A. Banini, Arun J. Sanyal. Current and future pharmacologic treatment of nonalcoholic steatohepatitisCurrent Opinion in Gastroenterology 2017; 33(3): 134 doi: 10.1097/MOG.0000000000000356
62
Chattraya Ngamlerst, Arunwan Udomkasemsab, Ratchanee Kongkachuichai, Karunee Kwanbunjan, Chaowanee Chupeerach, Pattaneeya Prangthip. The potential of antioxidant-rich Maoberry (Antidesma bunius) extract on fat metabolism in liver tissues of rats fed a high-fat dietBMC Complementary and Alternative Medicine 2019; 19(1) doi: 10.1186/s12906-019-2716-0
63
Vimala Ananthy, Raman Palanyswamy Priyadharsini, Umamaheswari Subramanian. Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive ReviewSBV Journal of Basic, Clinical and Applied Health Science 2021; 4(2): 39 doi: 10.5005/jp-journals-10082-03111
64
Mohamad Kareem Marrache, Don C. Rockey. Statins for treatment of chronic liver diseaseCurrent Opinion in Gastroenterology 2021; 37(3): 200 doi: 10.1097/MOG.0000000000000716
65
C. Moctezuma-Velázquez. Current treatment for non-alcoholic fatty liver diseaseRevista de Gastroenterología de México (English Edition) 2018; 83(2): 125 doi: 10.1016/j.rgmxen.2018.05.014
66
Umair Iqbal, Brandon Perumpail, Nimy John, Sandy Sallam, Neha Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed. Judicious Use of Lipid Lowering Agents in the Management of NAFLDDiseases 2018; 6(4): 87 doi: 10.3390/diseases6040087
67
Sven M. Francque, W. J. Kwanten, D. van der Graaff. Portal Hypertension in NASH: Is It Different from Other Aetiologies?Current Hepatology Reports 2019; 18(2): 134 doi: 10.1007/s11901-019-00459-z
68
Diana Barb, Kenneth Cusi. Reply to “statins and non-alcoholic steatohepatitis”Metabolism 2017; 66: e3 doi: 10.1016/j.metabol.2016.10.004
69
Rashid Ali Khan, Uma Bhandari, Prem Kapur, Abhinav Jain, Farrukh Farah. Effects of rosuvastatin (added to hypocaloric diet) on serum periostin, adiponectin, proinflammtory cytokines levels and hepatic steatosis in non-alcoholic fatty liver disease patients with dyslipidemiaClinical Epidemiology and Global Health 2019; 7(1): 53 doi: 10.1016/j.cegh.2017.12.010
70
Connie B. Newman, David Preiss, Jonathan A. Tobert, Terry A. Jacobson, Robert L. Page, Larry B. Goldstein, Clifford Chin, Lisa R. Tannock, Michael Miller, Geetha Raghuveer, P. Barton Duell, Eliot A. Brinton, Amy Pollak, Lynne T. Braun, Francine K. Welty. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart AssociationArteriosclerosis, Thrombosis, and Vascular Biology 2019; 39(2) doi: 10.1161/ATV.0000000000000073
71
B. V. M. Dasari, A. Pathanki, J. Hodson, K. J. Roberts, R. Marudanayagam, D. F. Mirza, J. Isaac, R. P. Sutcliffe, P. Muiesan. Propensity-matched analysis of the influence of perioperative statin therapy on outcomes after liver resectionBJS Open 2019; 3(4): 509 doi: 10.1002/bjs5.50155
72
Sergi Guixé-Muntet, Chang-Peng Zhu, Wei-Fen Xie, Jordi Gracia-Sancho. Novel therapeutics for portal hypertension and fibrosis in chronic liver diseasePharmacology & Therapeutics 2020; 215: 107626 doi: 10.1016/j.pharmthera.2020.107626
73
C. Moctezuma-Velázquez. Tratamiento actual de la enfermedad por hígado graso no alcohólicoRevista de Gastroenterología de México 2018; 83(2): 125 doi: 10.1016/j.rgmx.2017.10.003
74
Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver DiseaseBioMed Research International 2020; 2020: 1 doi: 10.1155/2020/4020249
75
Matthew Kappus, Manal Abdelmalek. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver TransplantationClinics in Liver Disease 2017; 21(2): 321 doi: 10.1016/j.cld.2016.12.006
76
David Niederseer, Bernhard Wernly, Elmar Aigner, Felix Stickel, Christian Datz. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic ConsiderationsJournal of Clinical Medicine 2021; 10(3): 467 doi: 10.3390/jcm10030467
77
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitisMetabolism 2017; 66: e1 doi: 10.1016/j.metabol.2016.10.006
78
Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios G. Athyros. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?Current Vascular Pharmacology 2019; 17(5): 425 doi: 10.2174/157016111705190703102816
79
Carlos Moctezuma-Velázquez, Juan G. Abraldes, Aldo J. Montano-Loza. The Use of Statins in Patients With Chronic Liver Disease and CirrhosisCurrent Treatment Options in Gastroenterology 2018; 16(2): 226 doi: 10.1007/s11938-018-0180-4
80
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitisJournal of Hepatology 2016; 64(1): 241 doi: 10.1016/j.jhep.2015.09.021